Publications and communications of Stéphanie Herkenne

Herkenne, S. (01 December 2023). 1. Mitochondria control the communication of cancer cells with the tumor microenvironment [Paper presentation]. Mitochondrie apoptosis and cancer meeting, coimbra, Portugal.

Herkenne, S. (02 October 2023). 2. MDVs control endosomal maturation [Paper presentation]. EMBO contacts sites meeting.

Marchesan, E., Alice Nardin, Sofia Mauri, Simone Di Paola, Monica Chinellato, Sophia von Stockum, Joy Chakraborty, Herkenne, S., Valentina Basso, Emilie Schrepfer, Oriano Marin, Laura Cendron, Diego L. Medina, Luca Scorrano, & Elena Ziviani. (2023). Activation of Ca2+ phosphatase Calcineurin regulates Parkin translocation to mitochondria and mitophagy. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/304655.

Herkenne, S. (06 September 2022). Mitochondria: new regulator of endosomal trafficking [Paper presentation]. GIGA day.

Herkenne, S. (24 June 2022). Mitochondria: new regulator of endosomal pathway [Paper presentation]. talk IBM.

NJOCK, M.-S.* , O'Grady, T.* , Nivelles, O., Lion, M., Jacques, S., Cambier, M., Herkenne, S., Muller, F., Christian, A., REMACLE, C., GUIOT, J., Rahmouni, S., Dequiedt, F.* , & Struman, I.*. (June 2022). Endothelial extracellular vesicles promote tumour growth by tumour-associated macrophage reprogramming. Journal of Extracellular Vesicles, 11 (6), 12228. doi:10.1002/jev2.12228
* These authors have contributed equally to this work.

Herkenne, S. (08 April 2022). Regulation of endosomal trafficking by mitochondrial dynamic and mitochondria-derived vesicles [Paper presentation]. Séminaire TELEVIE.

Herkenne, S. (17 March 2022). Mitochondrial dynamic regulates miRNA expression in breast cancer [Paper presentation]. Meeting NARILIS.

Zamberlan, M.* , Boeckx, A.* , Muller, F., Vinelli, F., Ek, O., Vianello, C., Coart, E., Shibata, K., Christian, A., Grespi, F., Giacomello, M., Struman, I., Scorrano, L.* , & Herkenne, S.*. (12 March 2022). Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. Journal of Experimental and Clinical Cancer Research, 41 (1), 95. doi:10.1186/s13046-022-02304-6
* These authors have contributed equally to this work.

Fontaine, M., Herkenne, S., Ek, O., Paquot, A., Boeckx, A., Paques, C., Nivelles, O., Thiry, M., & Struman, I. (2022). Extracellular Vesicles Mediate Communication between Endothelial and Vascular Smooth Muscle Cells. International Journal of Molecular Sciences, 23 (1). doi:10.3390/ijms23010331

Bean, C., Audano, A., Varanita, T., Favaretto, F., Medaglia, M., Gerdol, M., Pernas, L., Giacomello, M., Herkenne, S., Muniandy, M., Heinonen, S., Milan, G., Pallavicini, A., Pietiläinen, K., Vettor, R., Mitro, N., & Scorrano, L. (2021). The mitochondrial protein Opa1 promotes adipocyte browning that is dependent on urea cycle metabolites. Nature Metabolism. doi:10.1038/s42255-021-00497-2

Herkenne, S. (17 November 2021). the mitochondrial fission factor dynamin related protein 1 (DRP1) limits angiogenesis by interfering with VEGFR2 trafficking [Paper presentation]. Société française d'angiogenèse.

Herkenne, S., & Scorrano, L. (13 November 2020). OPA1, a new mitochondrial target in cancer therapy. Aging, 12, 20931-20933. doi:10.18632/aging.104207

Angioni, R., Liboni, C., Herkenne, S., Sanchez-Rodriguez, R., Borile, G., Marcuzzi, E., Cali, B., Muraca, M., & Viola, A. (2020). CD73 + extracellular vesicles inhibit angiogenesis through adenosine A 2B receptor signalling. Journal of Extracellular Vesicles. doi:10.1080/20013078.2020.1757900

Herkenne, S. (2020). mitochondria and vesicles link [Paper presentation]. Présentation young investigator.

Herkenne, S. (2020). Mitochondria and EVs [Paper presentation]. Young PI selection CECAD, Cologne, Germany.

Herkenne, S., ek, O., Zamberlan, M., Pellatiero, A., Chergova, M., chivite, L., Novotna, E., Rigoni, G., Fonseca, T., samardzic, D., Agnellini, A., Bean, C., Di Benedetto, G., Tiso, N., Argenton, F., viola, A., Sorianno, M., Giacommello, M., Ziviani, E., ... Scorrano, L. (2020). Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metabolism. doi:10.1016/j.cmet.2020.04.007

Zaninello, M., Palikaras, K., Naon, D., Iwata, K., Herkenne, S., Quintana-Cabrera, R., Semenzato, M., Grespi, F., Ross-Cisneros, F., Carelli, V., Sadun, A., Tavernarakis, N., & Scorrano, L. (2020). Inhibition of autophagy curtails visual loss in a model of autosomal dominant optic atrophy. Nature Communications. doi:10.1038/s41467-020-17821-1

Herkenne, S. (2019). Developmental and tumor angiogenesis requires changes in endothelial cell mitochondrial shape [Paper presentation]. 3rd retreat of the Department of Biology, University of Padova, Padova, Italy.

Herkenne, S. (2019). Developmental and tumor angiogenesis requires changes in endothelial cell mitochondria-shaping protein OPA1 [Paper presentation]. 6th Biannual Meeting on Mitochondria Apoptosis & Cancer, Prague, CSK.

Herkenne, S. (2019). 3. The mitochondrial fission factor Dynamin Related Protein 1 limits VEGF/VEGFR2 endocytic trafficking and angiogenesis [Paper presentation]. 3rd ESM-EVBO Conference, Maastricht, Netherlands.

Herkenne, S., & Herkenne, S. (2019). The mitochondrial fission factor Dynamin-related protein 1 (Drp1) limits VEGF/VEGFR2 endocytic trafficking and angiogenesis [Paper presentation]. meeting in Padova.

Herkenne, S. (15 October 2018). The mitochondria shaping protein Optic Atrophy 1 (OPA1) controls angiogenesis [Paper presentation]. Société française d'angiogenèse.

Loubiere, C., Clavel, S., Gilleron, J., Harisseh, R., Fauconnier, J., Ben-Sahra, I., Kaminski, L., Laurent, K., Herkenne, S., Lacas-Gervais, S., Ambrosetti, D., Alcor, D., Rocchi, S., Cormont, M., Michiels, J., Mari, B., mazure, N., scorrano, L., lacampagne, A., ... Bost, F. (2017). The energy disruptor metformin targets mitochondrial integrity via modification of calcium flux in cancer cells. Scientific Reports. doi:10.1038/s41598-017-05052-2

Naon, D., Zaninello, M., Giacommello, M., Varanita, T., Grespi, F., Lakshminaranayan, S., Serafini, A., Semenzato, M., Herkenne, S., Hernández-Alvarez, Zorzano, A., De Stefani, D., Dworn, G., & Scorrano, L. (2017). Reply to Filadi et al.: Does Mitofusin 2 tether or separate endoplasmic reticulum and mitochondria? Proceedings of the National Academy of Sciences of the United States of America.

Herkenne, S. (2016). The mitochondrial shaping protein Optic Atrophy 1 (OPA1) controls angiogenesis, lymphangiogenesis and tumor growth [Paper presentation]. Mito Insbruck-Padova, Insbruck, Austria.

Herkenne, S. (2016). The mitochondrial shaping protein Optic Atrophy 1 (OPA1) controls angiogenesis and tumor growth [Paper presentation]. pADOVA-iNBRUCK MEETING.

naon, D., zaninello, M., giacomello, M., varanita, T., grespi, F., Lakshminaranayan, S., Serafini, A., semenzato, M., Herkenne, S., hernadez-alvarez, M., zorzano, A., De stefani, D., Dworn, G., & Scorrano, L. (2016). Critical reappraisal confirms that Mitofusin 2 is anendoplasmic reticulum–mitochondria tether. Proceedings of the National Academy of Sciences of the United States of America. doi:10.1073/pnas.1606786113

Herkenne, S. (2015). The mitochondria shaping protein Optic Atrophy 1 (OPA1) controls angiogenesis [Paper presentation]. Société française d'angiogenèse, Paris, France.

Herkenne, S. (2015). The mitochondria shaping protein Optic Atrophy 1 (OPA1) controls angiogenesis [Paper presentation]. 6ème congrès de la SFA à Paris.

Herkenne, S., Paques, C., Nivelles, O., Lion, M., BAJOU, K., Pollenus, T., Fontaine, M., Carmeliet, P., Martial, J., Nguyen, N.-Q.-N., & Struman, I. (2015). The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis. Science Signaling, 8 (403), 117. doi:10.1126/scisignal.aaa2403

Herkenne, S. (21 October 2014). Involvement of mitochondrial dynmics in the regulation of angiogenesis [Paper presentation]. EMBO interview.

Paques, C., Herkenne, S., Pollenus, T., & Struman, I. (May 2014). Growth Factors-Induced Angiogenesis Requires uPAR on Endothelial Cells [Poster presentation]. Giga Cancer Day, Liège, Belgium.

Bajou, K.* , Herkenne, S.* , Thijssen, V. L., D'Amico, S., Nguyen, N.-Q.-N., Bouche, A., Tabruyn, S., Srahna, M., Carabin, J.-Y., Nivelles, O., Paques, C., Cornelissen, Y., Lion, M., Noël, A., Gils, A., Vinckier, S., Declerck, P. J., Griffioen, A. W., Dewerchin, M., ... Struman, I. (2014). PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature Medicine, (7), 741. doi:10.1038/nm.3552
* These authors have contributed equally to this work.

Herkenne, S. (2013). Détermination du rôle de l'interactome PAI-1/uPA/uPAR dans l'angiogenèse [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/153730

Paques, C., Herkenne, S., & Struman, I. (2013). Tumor-Induced Angiogenesis Requires uPAR on Endothelial Cells [Poster presentation]. Giga Cancer Day.

Herkenne, S., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (19 May 2012). Implication of the PAI-1/uPA/uPAR signalosome in the antiangiogenic action of 16K prolactin [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (April 2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K prolactin [Poster presentation]. Biomedica, Liège, Belgium.

Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K hPRL [Poster presentation]. Keystone symposia on Angiogenesis: Advances in Basic Science and Therapeutic Applications, Snowbird, United States - Utah.

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (May 2011). The antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation [Poster presentation]. 4th International Meeting on Angiogenesis, Amsterdam, Netherlands.

Bajou, K., Herkenne, S., Thijssen, V. L., D'Amico, S., Srahna, M., Carabin, J.-Y., Gils, A., Declerck, P. J., Griffioen, A. W., Martial, J., & Struman, I. (January 2011). PAI-1 mediates antiangiogenic and fibrinolytic actions of prolactin/growth hormone 16-14K fragments [Poster presentation]. Giga-Day Symposia, Liège, Belgium.

Herkenne, S., Bajou, K., D'Amico, S., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2011). Implication of the PAI-1/uPA/uPAR complex in the effects of the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium.

Kinet, V., Castermans, K., Herkenne, S., Maillard, C., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (2011). The Angiostatic Protein 16K Human Prolactin Significantly Prevents Tumor-Induced Lymphangiogenesis by Affecting Lymphatic Endothelial Cells. Endocrinology. doi:10.1210/en.2011-1081

Herkenne, S., Bajou, K., D'Amico, S., Martial, J., & Struman, I. (21 May 2010). Study of the signalling pathway of 16K PRL and 14K GH for mediate their anti-angiogenic effect [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.